Preparing Naurex for an Optimal Exit

The situation: Naurex and its cutting-edge neuroscience drugs were relatively unknown in the biotech and pharmaceutical space. The company sought to elevate its profile as it planned for what was next, with the possibility of going public or being acquired. Executives hired CanaleComm to craft a compelling corporate story and boost visibility among investors and pharma companies, crafting the most advantageous position for its next chapter.

The plan: CanaleComm conducted a half-day positioning workshop to create new and differentiating corporate messaging centered on the unique benefits of Naurex’s platform and proprietary compounds. Targeted media outreach followed, with CanaleComm leveraging three critical announcements—including promising clinical trial data—over a six-month period in a rapid-fire approach to gain wide visibility.

The results: The story of Naurex appeared in every major industry trade publication as well as The New York Times, Forbes and Fast Company. Naurex achieved strong interest from potential acquirers and investors, ultimately accepting an offer to sell its depression drugs in July 2015 to Allergan for $560 million in cash and significant milestones.